|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT03483922 |
|
Date of registration:
|
20/03/2018 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
HCC Screening Using DNA Methylation Changes in ctDNA
|
|
Scientific title:
|
Clinical Trials on Detection of Hepatocellular Carcinoma With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells |
|
Date of first enrolment:
|
August 20, 2018 |
|
Target sample size:
|
400 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT03483922 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Bangladesh
| | | | | | | |
|
Contacts
|
|
Name:
|
Wasif Ali Khan, PhD |
|
Address:
|
|
|
Telephone:
|
880-2-9827057 |
|
Email:
|
wakhan@icddrb.org |
|
Affiliation:
|
|
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Confirmed diagnosis of HCC by EASL-EORTC guidelines
- Confirmed hepatitis B diagnosis for HepB patients using AASLD practice guidelines.
Exclusion Criteria for HCC:
- Cirrhosis, any other known inflammatory disease (bacterial or viral infection with the
exception of hepatitis B or C, diabetes, asthma, autoimmune disease, active thyroid
disease) which could alter T cells and monocytes characteristics
- Other cancers.
Exclusion Criteria for HepB:
- Diagnosis of HCC or any other cancer.
Exclusion Criteria for Healthy Controls:
- Any known inflammatory or infectious disease including HepB and HepC
- Chronic diseases,
- Cancer
- Medications or drug use
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Hepatocellular Carcinoma
|
|
Intervention(s)
|
|
Diagnostic Test: ctDNA methylation in and it's Correlation wth Development and prediction of HCC
|
|
Primary Outcome(s)
|
|
DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of HCC
[Time Frame: 6 months to 1 year]
|
|
Secondary ID(s)
|
|
HKG-Bng-HCC-100
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|